Celldex Therapeutics reported $534.66M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Agenus USD 133.44M 514K Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Celldex Therapeutics USD 534.66M 69.68M Dec/2025
Glaxosmithkline GBP 23.59B 390.44M Dec/2025
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Northwest Biotherapeutics USD 7.2M 1.04M Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Roche Holding CHF 38.73B 3.03B Dec/2025